Arcturus, a new COVID-19 sub-variant, has caught the attention of the World Health Organization (WHO). The new omicron variant, XBB.1.16, causes familiar symptoms of previous variants of coronavirus.

São Paulo's Municipal Health Secretariat reported this week the first case of variant XBB.1.16 of Covid-19, also known as Arcturus in a 75-year-old man, bedridden and with comorbidities ...

Arcturus Therapeutics (ARCT) had a challenging fourth quarter, with revenue and earnings falling short of analyst ...

A new variant of the novel coronavirus called EG.5 is spreading in Japan, with experts expecting it to be the dominant strain in the country by mid-September. Though there is no evidence that EG.

How do variants work? At first, SARS-CoV-2 followed the slow and steady course that scientists had expected based on other coronaviruses. Its evolutionary tree gradually split into branches ...

Arcturus Therapeutics and CSL's COVID-19 vaccine Kostaive has been approved ... 1 subtype of Omicron variant BA.2.86, which is still one of the main strains currently circulating in Europe.

Arcturus received approval from the European Commission (EC) in February for KOSTAIVE, the world’s first approved sa-mRNA COVID-19 vaccine. The centralized marketing authorization of KOSTAIVE ...

As COVID-19 ... virus variants, the likelihood of optimizing KOSTAIVE’s formulation and completing technical enhancements, and the impact of general business and economic conditions. Arcturus ...